title: Soluble and insoluble nickel compounds exert a differential inhibitory effect on cell growth through IKKalpha-dependent cyclin D1 down-regulation.
abstract: It is well-known that insoluble nickel compounds possess much more potent carcinogenic activities as compared with soluble nickel compounds. Although it is assumed that the different entry and clearance rate are responsible for the difference, the mechanisms underlying the different carcinogenic activities are still not well understood yet. In the present study, we found that exposure to soluble, but not insoluble nickel compounds, caused a significant inhibition of cell growth and G1/G0 cell cycle arrest, which was concomitant with a marked down-regulation of cylin D1, an essential nuclear protein for controlling G1/S transition, while both soluble and insoluble nickel compounds showed similar effects on NFkappaB activation, HIF-1alpha protein accumulation and TNF-alpha transcription and CAP43 protein expression at same doses range. The down-regulation of cyclin D1 is due to protein degradation rather than inhibition of transcription, because the nickel compounds treatment did not change cyclin D1 mRNA level, while MG132, the proteasome inhibitor, can rescue the degradation of cyclin D1 caused by soluble nickel compound. Moreover, the soluble nickel-induced cyclin D1 degradation is dependent on its Thr286 residue and requires IKKalpha, but not HIF-1alpha, which are both reported to be involved in cyclin D1 down-regulation. Taken together, we demonstrate that soluble, but not insoluble nickel compound, is able to cause cyclin D1 degradation and a cell growth arrest in an IKKalpha-dependent manner. Given the role of cyclin D1 and cell proliferation in carcinogenesis, we anticipate that the different effects of soluble and insoluble nickel compounds on cyclin D1 degradation and cell growth arrest may at least partially account for their different carcinogenic activities.
authors.affiliation: Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, USA.
authors.forename: Weiming
authors.initials: W
authors.lastname: Ouyang
authors.forename: Dongyun
authors.initials: D
authors.lastname: Zhang
authors.forename: Jingxia
authors.initials: J
authors.lastname: Li
authors.forename: Udit N
authors.initials: UN
authors.lastname: Verma
authors.forename: Max
authors.initials: M
authors.lastname: Costa
authors.forename: Chuanshu
authors.initials: C
authors.lastname: Huang
mesh_terms: D000818:Animals; D001483:Base Sequence; D002273:Carcinogens / Q000633:toxicity; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D051550:I-kappa B Kinase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D009532:Nickel / Q000633:toxicity*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012995:Solubility
chemical_list: C530104:CCND1 protein, human; D002273:Carcinogens; C530105:Ccnd1 protein, mouse; D017931:DNA Primers; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D012333:RNA, Messenger; D019938:Cyclin D1; C022838:nickel chloride; D009532:Nickel; C496559:CHUK protein, human; C496564:Chuk protein, mouse; D051550:I-kappa B Kinase; C017558:nickel sulfide; C017557:nickel subsulfide
references.citation: Mutat Res. 2005 Dec 30;592(1-2):79-88
references.pmid: 16009382
references.citation: Ann N Y Acad Sci. 2003 Mar;983:151-60
references.pmid: 12724220
references.citation: Carcinogenesis. 1995 Feb;16(2):193-204
references.pmid: 7859348
references.citation: Natl Toxicol Program Tech Rep Ser. 1996 Jul;453:1-365
references.pmid: 12594522
references.citation: Cancer Res. 2000 Jan 1;60(1):38-41
references.pmid: 10646848
references.citation: Regul Toxicol Pharmacol. 2000 Apr;31(2 Pt 1):231-41
references.pmid: 10854128
references.citation: Carcinogenesis. 2006 Jul;27(7):1481-8
references.pmid: 16522665
references.citation: Mol Cell Biol. 2001 Jun;21(12):3986-94
references.pmid: 11359906
references.citation: Met Ions Biol Syst. 1999;36:445-83
references.pmid: 10093933
references.citation: Nature. 1993 Dec 16;366(6456):704-7
references.pmid: 8259215
references.citation: Scand J Work Environ Health. 1990 Feb;16(1 Spec No):1-82
references.pmid: 2185539
references.citation: J Nutr. 1975 Apr;105(4):452-8
references.pmid: 1113210
references.citation: Cancer Res. 1999 Oct 1;59(19):4876-81
references.pmid: 10519399
references.citation: Curr Opin Cell Biol. 2003 Apr;15(2):158-63
references.pmid: 12648671
references.citation: Environ Health Perspect. 2002 Oct;110 Suppl 5:841-4
references.pmid: 12426143
references.citation: Natl Toxicol Program Tech Rep Ser. 1996 Jul;451:1-381
references.pmid: 12594524
references.citation: Carcinogenesis. 2006 Apr;27(4):864-73
references.pmid: 16387740
references.citation: Cancer Res. 2005 Oct 15;65(20):9287-93
references.pmid: 16230390
references.citation: Nature. 2004 Nov 18;432(7015):316-23
references.pmid: 15549093
references.citation: Mutagenesis. 2004 Jan;19(1):35-41
references.pmid: 14681311
references.citation: EMBO J. 1998 Jun 1;17(11):3005-15
references.pmid: 9606183
references.citation: J Nutr. 1974 Feb;104(2):239-43
references.pmid: 4810985
references.citation: Genes Dev. 1997 Apr 15;11(8):957-72
references.pmid: 9136925
references.citation: Regul Toxicol Pharmacol. 2000 Apr;31(2 Pt 1):210-30
references.pmid: 10854127
references.citation: Diabetes. 2002 Nov;51(11):3290-9
references.pmid: 12401721
references.citation: Annu Rev Pharmacol Toxicol. 1999;39:295-312
references.pmid: 10331086
references.citation: J Natl Cancer Inst. 1975 May;54(5):1165-72
references.pmid: 165308
references.citation: Cancer Res. 1997 Apr 15;57(8):1569-74
references.pmid: 9108461
references.citation: Carcinogenesis. 1983;4(3):275-9
references.pmid: 6831634
references.citation: Prostate. 2003 Jan 1;54(1):58-67
references.pmid: 12481256
references.citation: Toxicol Appl Pharmacol. 1997 Mar;143(1):152-66
references.pmid: 9073603
references.citation: J Environ Pathol Toxicol Oncol. 2000;19(3):307-18
references.pmid: 10983897
references.citation: Res Commun Chem Pathol Pharmacol. 1976 Jun;14(2):319-30
references.pmid: 940963
references.citation: Scand J Work Environ Health. 1989 Feb;15(1):1-12
references.pmid: 2646706
references.citation: Cancer Res. 2001 Nov 15;61(22):8051-7
references.pmid: 11719426
references.citation: Environ Health Perspect. 2002 Oct;110 Suppl 5:835-9
references.pmid: 12426142
references.citation: J Biol Chem. 2004 Dec 31;279(53):56061-6
references.pmid: 15513923
references.citation: Prog Clin Biol Res. 1991;369:291-301
references.pmid: 1946526
references.citation: Natl Toxicol Program Tech Rep Ser. 1996 Jul;454:1-380
references.pmid: 12587012
references.citation: Mol Cell Biochem. 2001 Jun;222(1-2):159-71
references.pmid: 11678598
references.citation: Toxicol Pathol. 1987;15(2):245-58
references.pmid: 3112923
references.citation: Mol Cell Biochem. 2005 Nov;279(1-2):45-67
references.pmid: 16283514
references.citation: J Biol Chem. 2005 Oct 7;280(40):33945-52
references.pmid: 16103118
references.citation: Cancer Res. 2003 Jul 1;63(13):3524-30
references.pmid: 12839937
references.citation: Cancer Res. 2004 Dec 15;64(24):9027-34
references.pmid: 15604268
references.citation: Exp Dermatol. 2004 Jan;13(1):18-26
references.pmid: 15009112
references.citation: Cancer Res. 1987 Jul 15;47(14):3815-23
references.pmid: 3594439
references.citation: Fundam Appl Toxicol. 1995 Dec;28(2):232-44
references.pmid: 8835233
references.citation: Cell. 1997 Oct 17;91(2):243-52
references.pmid: 9346241
references.citation: Regul Toxicol Pharmacol. 2003 Apr;37(2):173-90
references.pmid: 12726752
references.citation: Cell. 2001 Dec 14;107(6):763-75
references.pmid: 11747812
references.citation: Cancer Res. 2004 Jan 1;64(1):94-101
references.pmid: 14729612
references.citation: Toxicol Lett. 1988 Oct;43(1-3):151-73
references.pmid: 3051522
references.citation: FEBS Lett. 2008 Apr 2;582(7):1111-6
references.pmid: 18328826
references.citation: EMBO J. 2003 May 1;22(9):2036-46
references.pmid: 12727871
references.citation: Nature. 2004 Nov 18;432(7015):298-306
references.pmid: 15549091
references.citation: IARC Monogr Eval Carcinog Risks Hum. 1990;49:1-648
references.pmid: 2232124
references.citation: Carcinogenesis. 2003 Jul;24(7):1159-65
references.pmid: 12807763
references.citation: J Environ Monit. 2003 Apr;5(2):206-9
references.pmid: 12729255
references.citation: Nature. 1995 Dec 21-28;378(6559):785-9
references.pmid: 8524413
references.citation: Genes Dev. 2000 Dec 15;14(24):3102-14
references.pmid: 11124803
references.citation: Scand J Work Environ Health. 1993;19 Suppl 1:75-80
references.pmid: 8159980
references.citation: Mol Cell Biol. 1997 Dec;17(12):7362-74
references.pmid: 9372967